system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: ATP Binding Cassette Transporter, Subfamily B, ATP Binding Cassette Transporter, Subfamily B, Member 1, Adolescent, Adult, Aged, Area Under Curve, Child, Diarrhea, Dose-Response Relationship, Drug, Female, Genetic Association Studies, Genetic Predisposition to Disease, Humans, Incidence, Kidney Transplantation, Leukopenia, Liver-Specific Organic Anion Transporter 1, Male, Middle Aged, Mycophenolic Acid, Netherlands, Organic Anion Transporters, Organic Anion Transporters, Sodium-Independent, Solute Carrier Organic Anion Transporter Family Member 1B3.
user
Is mycophenolic acid-related diarrhea associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients? Context: We investigated the association between genetic polymorphisms in ABCB1 and SLCO1B and mycophenolic acid (MPA) pharmacokinetics, and MPA-related diarrhea and leukopenia in 338 kidney transplant recipients. A total of 338 patients participating in an international, randomized-controlled clinical trial were genotyped for ABCB1 and SLCO1B. Patients were all treated with mycophenolate mofetil and either cyclosporine or tacrolimus. MPA-area under the curve (AUCs), MPA-glucuronide AUCs and acylglucuronide-AUCs were measured on days 3 and 10, and months 1, 3, 6, and 12 after kidney transplantation. The risk of developing diarrhea was 1.8-fold higher in patients cotreated with tacrolimus compared with patients cotreated with cyclosporine (95% confidence interval: 1.03-3.13; P=0.038). ABCB1 and SLCO1B SNPs were not associated with dose-adjusted exposure to MPA, MPA-glucuronide, nor acylglucuronide-MPA nor with the incidence of diarrhea or leukopenia.
assistant
Genotyping for ABCB1 or SLCO1B pretransplantation is unlikely to be of clinical value for individualization of MPA therapy. Final Decision: no